# Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS

> **NCT01540812** · — · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 418 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Vincristine in induction
- **DRUG:** Daunorubicin in induction
- **DRUG:** Prednisone in induction
- **DRUG:** Metotrexato in induction
- **DRUG:** Cytarabine in induction
- **DRUG:** Hydrocortisone in induction
- **DRUG:** Idarubicin in induction-2
- **DRUG:** Fludarabine in induction-2
- **DRUG:** Ara-C in induction-2
- **DRUG:** G-CSF in induction-2
- **DRUG:** Dexamethasone in consolidation-1
- **DRUG:** Vincristrine in consolidation-1
- **DRUG:** Metotrexato in consolidation-1
- **DRUG:** PEG-ASP in consolidation-1
- **DRUG:** Dexamethasone in consolidation-2
- **DRUG:** ARA-C in consolidation-2
- **DRUG:** PEG-ASP in consolidation-2
- **DRUG:** Dexamethasone in consolidation-3
- **DRUG:** Vincristine in consolidation-3
- **DRUG:** Metotrexato in consolidation-3

## Key facts

- **NCT ID:** NCT01540812
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2019-11-20
- **Final completion:** 2019-12-01
- **Target enrollment:** 418 (ACTUAL)
- **Last updated:** 2020-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01540812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01540812, "Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01540812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*